Drug intelligence / Profile preview

CBP-312

Development stage: Unknown
Lead developer: Connect Biopharma
Modality: Small Molecules
Administration: Subcutaneous

Overview

**CBP-312** is an immune modulator in early development by Connect Biopharma, a biotech company focused on inflammatory diseases. It is part of their pipeline alongside other candidates like CBP-174, CBP-233, and CBP-201 for atopic dermatitis and related conditions. Limited public data exists on its specific mechanism, but it is classified as a **GPCR modulator**, suggesting potential targeting of G protein-coupled receptors involved in immune regulation.[1][5]

Beyond the preview

Go deeper on CBP-312.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBP-312.

Explore the full profile